David Grinblatt to Rituximab
This is a "connection" page, showing publications David Grinblatt has written about Rituximab.
Connection Strength
0.199
-
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer. 2017 03 16; 17(1):198.
Score: 0.136
-
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020 04 14; 4(7):1407-1418.
Score: 0.042
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.021